Literature DB >> 21115035

The treatment of cognitive impairment in schizophrenia.

Donald C Goff1, Michele Hill, Deanna Barch.   

Abstract

Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21115035      PMCID： PMC3114283          DOI： 10.1016/j.pbb.2010.11.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN： 0091-3057            Impact factor:   3.533


  150 in total

1.  Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.

Authors:  T Sumiyoshi; M Matsui; S Nohara; I Yamashita; M Kurachi; C Sumiyoshi; K Jayathilake; H Y Meltzer
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

2.  Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.

Authors:  Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Susan J Cooley; Ann Louise DiBarry; Debra M Montrose; Matcheri S Keshavan
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

3.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

4.  Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia.

Authors:  Chantal Schlumberger; Małgorzata Pietraszek; Andreas Gravius; Wojciech Danysz
Journal:  Pharmacol Biochem Behav       Date:  2009-12-05       Impact factor: 3.533

5.  Stability and course of neuropsychological deficits in schizophrenia.

Authors:  R K Heaton; J A Gladsjo; B W Palmer; J Kuck; T D Marcotte; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  2001-01

6.  Impact of modafinil on prefrontal executive function in schizophrenia.

Authors:  Michael D Hunter; Venkatasubramanian Ganesan; Iain D Wilkinson; Sean A Spence
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

7.  Hippocampal plasticity in response to exercise in schizophrenia.

Authors:  Frank-Gerald Pajonk; Thomas Wobrock; Oliver Gruber; Harald Scherk; Dorothea Berner; Inge Kaizl; Astrid Kierer; Stephanie Müller; Martin Oest; Tim Meyer; Martin Backens; Thomas Schneider-Axmann; Allen E Thornton; William G Honer; Peter Falkai
Journal:  Arch Gen Psychiatry       Date:  2010-02

8.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

9.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

10.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.

Authors:  Onder Tuğal; Kâzm M Yazici; A Elif Anil Yağcioğlu; Ahmet Göğüş
Journal:  Int J Neuropsychopharmacol       Date:  2004-01-23       Impact factor: 5.176
View more
  50 in total

1.  The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?

Authors:  C Quisenaerts; M Morrens; W Hulstijn; E de Bruijn; M Timmers; J Streffer; J De la Asuncion; G Dumont; B Sabbe
Journal:  Psychopharmacology (Berl)       Date:  2014-02       Impact factor: 4.530

Review 2.  Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors.

Authors:  Alkomiet Hasan; Amanda Mitchell; Anja Schneider; Tobias Halene; Schahram Akbarian
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-02-05       Impact factor: 5.270

3.  Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids.

Authors:  Yusuke Kato; Niyada Hin; Nobuo Maita; Ajit G Thomas; Sumire Kurosawa; Camilo Rojas; Kazuko Yorita; Barbara S Slusher; Kiyoshi Fukui; Takashi Tsukamoto
Journal:  Eur J Med Chem       Date:  2018-09-18       Impact factor: 6.514

Review 4.  Kraepelin revisited: schizophrenia from degeneration to failed regeneration.

Authors:  P Falkai; M J Rossner; T G Schulze; A Hasan; M M Brzózka; B Malchow; W G Honer; A Schmitt
Journal:  Mol Psychiatry       Date:  2015-03-31       Impact factor: 15.992

Review 5.  Cortical basket cell dysfunction in schizophrenia.

Authors:  Allison A Curley; David A Lewis
Journal:  J Physiol       Date:  2012-01-04       Impact factor: 5.182

6.  Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning.

Authors:  W Bailey Glen; Bryant Horowitz; Gregory C Carlson; Tyrone D Cannon; Konrad Talbot; J David Jentsch; Antonieta Lavin
Journal:  Hippocampus       Date:  2013-11-12       Impact factor: 3.899

7.  Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Authors:  Richard S E Keefe; Sophia Vinogradov; Alice Medalia; Peter F Buckley; Stanley N Caroff; Deepak C D'Souza; Phillip D Harvey; Karen A Graham; Robert M Hamer; Stephen M Marder; Del D Miller; Stephen J Olson; Jayendra K Patel; Dawn Velligan; Trina M Walker; Adam J Haim; T Scott Stroup
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

8.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

9.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

10.  The diminished pipeline for medications to treat mental health and substance use disorders.

Authors:  Peggy L O'Brien; Cindy Parks Thomas; Dominic Hodgkin; Katharine R Levit; Tami L Mark
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.